Cargando…

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options

Neovascular age-related macular degeneration (nAMD) is a common world-wide cause of visual loss. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are an effective means to treat nAMD and reduce its impact on vision compared to either sham treatment or photodynamic therapy. Cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Colin S, Ngo, Wei Kiong, Chay, Isaac W, Ting, Dominic S, Sadda, SriniVas R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965014/ https://www.ncbi.nlm.nih.gov/pubmed/35368240 http://dx.doi.org/10.2147/OPTH.S231913

Ejemplares similares

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic
por: Corradetti, Giulia, et al.
Publicado: (2020)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
por: Gale, Richard P., et al.
Publicado: (2019)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

The COVID-19 Pandemic and Ophthalmic Care: A Qualitative Study of Patients with Neovascular Age-Related Macular Degeneration (nAMD)
por: O’Connor, Seán R., et al.
Publicado: (2022)

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment
por: Holz, Frank G., et al.
Publicado: (2022)

Relationship Between Drusen Height and OCT Biomarkers of Atrophy in Non-Neovascular AMD
por: Au, Adrian, et al.
Publicado: (2022)

Choriocapillaris Flow Deficits and Treatment-Naïve Macular Neovascularization Secondary to Age-Related Macular Degeneration
por: Scharf, Jackson M., et al.
Publicado: (2020)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan, Colin S, et al.
Publicado: (2017)

Interleukin-1β Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV)
por: Zhao, Min, et al.
Publicado: (2015)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab
por: Hayashi-Mercado, Ricardo, et al.
Publicado: (2022)

Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy
por: Bousquet, Elodie, et al.
Publicado: (2022)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study
por: Tan, Colin S., et al.
Publicado: (2020)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Optical Coherence Tomography Angiography of the Choriocapillaris in Age-Related Macular Degeneration
por: Scharf, Jackson, et al.
Publicado: (2021)

Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis
por: Sadda, SriniVas, et al.
Publicado: (2022)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Focus on external limiting membrane and ellipsoid zone in diabetic macular edema
por: Saxena, Sandeep, et al.
Publicado: (2021)

Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study
por: Chan, Clement K., et al.
Publicado: (2020)

Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)—a phase III, prospective, multicentre, randomized study: design and methods
por: Coulibaly, Leonard M., et al.
Publicado: (2022)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Twelve per cent of 6142 eyes treated for neovascular age‐related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
por: Schroeder, Marion, et al.
Publicado: (2019)

Association of OCT-Derived Drusen Measurements with AMD-Associated Genotypic SNPs in the Amish Population
por: Chavali, Venkata Ramana Murthy, et al.
Publicado: (2015)

Communicating with patients with nAMD and their families during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME
por: Avery, Robert L., et al.
Publicado: (2023)

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Correlation between Macular Neovascularization (MNV) Type and Druse Type in Neovascular Age-Related Macular Degeneration (AMD) Based on the CONAN Classification
por: Muth, Daniel Rudolf, et al.
Publicado: (2022)

Reverse engineering for reconstructing baseline features of dry age-related macular degeneration in optical coherence tomography
por: Wang, Shuxian, et al.
Publicado: (2022)

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD
por: Ziemssen, Focke, et al.
Publicado: (2022)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
por: Hoffmann, Laura, et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

Risk Factors for Progression of Age-Related Macular Degeneration: Population-Based Amish Eye Study
por: Nittala, Muneeswar G., et al.
Publicado: (2022)

Choriocapillaris Impairment Is Associated With Delayed Rod-Mediated Dark Adaptation in Age-Related Macular Degeneration
por: Kar, Deepayan, et al.
Publicado: (2023)

Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab
por: Corradetti, Giulia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fmehrbctqch3cbthp1725e9iae